High call volume

Our customer contact center is currently experiencing high call volumes. We thank you for your patience.

Show More

Important Notification Regarding Renflexis (Infliximab-abda)

The Food and Drug Administration (FDA) recently approved biosimilar products that can be utilized in place of reference drugs in most clinical circumstances. Biosimilar products offer additional safe and cost-effective options. The FDA approved several biosimilars for Remicade® (infliximab) including Infliximab(unbranded Remicade).

Remicade and its biosimilar products, Infliximab (unbranded Remicade),infliximab-dyyb (Inflectra®), infliximab-abda (Renflexis®)and infliximab-axxq (AvsolaTM) are part of the BCBSND Infliximab medical policy.

Disregard previous Renflexis (infliximab-abda) change
Blue Cross Blue Shield of North Dakota (BCBSND) is no longer moving forward with changing Renflexis to a non-preferred agent on April, 1, 2022. Members may continue to receive Renflexis without making therapy changes if they have a current prior approval. BCBSND will contact members for awareness. Members whose Renflexis (Q5104) prior approval dates were adjusted will receive a letter with their new approval dates.